Scientists identify vitamin B weakness in aggressive brain cancer, enabling diet-based treatment

Researchers working across five European institutions have identified a metabolic weak point in glioblastoma, one of the brain's most lethal cancers, that could be targeted through a combination of medication and dietary intervention. The discovery, published in Science Advances, centers on how steroid drugs fundamentally alter the way glioblastoma cells process vitamin B3—a shift that creates an exploitable vulnerability in tumour metabolism.

The team, which included scientists from the Cancer Research UK Scotland Institute in Glasgow, found that when steroids are introduced, glioblastoma cells become dependent on specific metabolic pathways. By simultaneously restricting methionine, an amino acid present in many foods, researchers were able to starve the cancer cells of the compounds they need to proliferate. In preclinical models, this combined approach—steroid treatment paired with dietary modification—slowed tumour growth measurably.

Dr Saverio Tardito, one of the lead researchers, described the finding as a previously unrecognized vulnerability that opens new avenues for patient care. The significance lies not just in the discovery itself, but in its practical application: unlike many experimental cancer treatments that remain theoretical, this approach builds on drugs already in clinical use and relies on dietary changes that patients could potentially implement alongside conventional therapy. The research suggests that personalised nutrition strategies might enhance the effectiveness of existing treatments rather than replace them.

Glioblastoma remains one of the most aggressive human cancers, characterized by rapid growth and poor survival rates. Patients and families have long awaited new treatment options that could extend survival or improve quality of life. The current standard of care—surgery, radiation, and chemotherapy—has seen limited advancement in recent decades, making discoveries that could slow progression particularly urgent.

Sam Godfrey, science engagement lead at Cancer Research UK, which partly funded the work, emphasized the human stakes. Treatments that could buy patients additional time with their families represent a meaningful breakthrough in a disease where time is scarce. The research demonstrates how understanding cancer's metabolic dependencies—the specific nutrients and chemical processes tumour cells require to survive—can translate into practical interventions.

The path from preclinical findings to patient treatment remains substantial. The research was conducted in laboratory models, not human subjects, and the next phase would involve clinical trials to determine whether the metabolic vulnerability identified in cells and animal models translates to real-world benefit. Questions about dosing, timing, dietary specificity, and which patients might benefit most would need to be answered through rigorous testing.

Still, the discovery represents a shift in how researchers approach glioblastoma treatment. Rather than seeking only new drugs, this work suggests that existing medications might be deployed more effectively when combined with targeted dietary strategies. For a disease where options have been limited, that possibility—that the answer might lie partly in what patients eat—offers a different kind of hope.